The increasing incidence of early-onset cancer worldwide has sparked extensive research efforts aimed at elucidating the unique biology and challenges of younger patients. Lung cancer has long been associated with older age, and while its overall incidence has declined alongside other smoking-related cancers, recent trends reveal shifting patterns of disease – more young people, especially women, are being diagnosed with lung cancer. These patients often harbor oncogenic mutations in their cancer, have advanced disease, and are less likely to have had a smoking history. Striking differences among geographic and ethnic populations warrant dedicated study. In today’s era of personalized medicine, it is crucial to deepen our understanding of early-onset lung cancer to optimize both treatment and prevention.
This collection seeks to bring together diverse voices from around the world to explore the intricate interplay between genetic and environmental factors in the development of lung cancer in young adults. We will examine causes, molecular characteristics, and treatment, with a focus on global trends, perspectives, and disparities. Work on genetic factors, familial predisposition, as well as environmental risks such as air pollution and radon exposure, are welcome. Innovative methods like gut microbiome research, molecular biology, and immunology, may shed light on the biological underpinnings of disease. The collection will address tailored management strategies for young patients, including fertility preservation, psychosocial considerations, and balancing treatment efficacy with toxicity.
We invite contributions from researchers, clinicians, experts, patients, and patient advocates, including original research, basic, translational, and clinical studies, reviews, case reports and commentaries on topics such as:
• Global trends and epidemiology;
• Screening, early detection and prevention;
• Ancestry, ethnicity, and genetic factors;
• Environmental exposures: air pollution, radon, and more;
• Exposome and other risk factors;
• Basic and translational research;
• Palliative, supportive and integrative care, drugs, surgery, radiotherapy;
• Short- and long-term side effects;
• Fertility, pregnancy, and survivorship;
• Psychosocial challenges and advocacy.
Please note: Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Please note the following conflict of interest disclosures:
Ilit Turgeman – Educational activities: AstraZeneca, Bristol-Myers Squibb, Medison, Merck Sharp and Dohme, Merck Serono, Roche. Research grants: Gilead, Pfizer. Conference accommodation: Merck Serono, Roche.
Brian Henick – Honoraria: OncLive/MJH Life Sciences, DAVA Oncology. Consulting or Advisory Role: AstraZeneca, IDEAYA Biosciences, Jazz Pharmaceuticals, Sorrento Therapeutics, Genentech/Roche, Regeneron, Bristol Myers Squibb. Research Funding: NexImmune, Genentech/Roche, Johnson & Johnson/Janssen, Stand Up 2 Cancer, V Foundation.
Laura Mezquita – Educational activities: Bristol-Myers Squibb, AstraZeneca, Roche, Takeda, Janssen, MSD, Radonova. Consulting or Advisory role: Roche, Takeda, Janssen, MSD. Research Grants: Amgen, Inivata, AstraZeneca, Gilead. Travel, Accommodations and Expenses: Bristol-Myers Squibb, Roche, Takeda, AstraZeneca, Janssen.
Keywords:
Global oncology, adolescent and young adult oncology, etiology, genetics, carcinogens, ethnicity, fertility, disparities, microbiome, biomarkers, oncogene driven lung cancer, immunotherapy, toxicity, palliation
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
The increasing incidence of early-onset cancer worldwide has sparked extensive research efforts aimed at elucidating the unique biology and challenges of younger patients. Lung cancer has long been associated with older age, and while its overall incidence has declined alongside other smoking-related cancers, recent trends reveal shifting patterns of disease – more young people, especially women, are being diagnosed with lung cancer. These patients often harbor oncogenic mutations in their cancer, have advanced disease, and are less likely to have had a smoking history. Striking differences among geographic and ethnic populations warrant dedicated study. In today’s era of personalized medicine, it is crucial to deepen our understanding of early-onset lung cancer to optimize both treatment and prevention.
This collection seeks to bring together diverse voices from around the world to explore the intricate interplay between genetic and environmental factors in the development of lung cancer in young adults. We will examine causes, molecular characteristics, and treatment, with a focus on global trends, perspectives, and disparities. Work on genetic factors, familial predisposition, as well as environmental risks such as air pollution and radon exposure, are welcome. Innovative methods like gut microbiome research, molecular biology, and immunology, may shed light on the biological underpinnings of disease. The collection will address tailored management strategies for young patients, including fertility preservation, psychosocial considerations, and balancing treatment efficacy with toxicity.
We invite contributions from researchers, clinicians, experts, patients, and patient advocates, including original research, basic, translational, and clinical studies, reviews, case reports and commentaries on topics such as:
• Global trends and epidemiology;
• Screening, early detection and prevention;
• Ancestry, ethnicity, and genetic factors;
• Environmental exposures: air pollution, radon, and more;
• Exposome and other risk factors;
• Basic and translational research;
• Palliative, supportive and integrative care, drugs, surgery, radiotherapy;
• Short- and long-term side effects;
• Fertility, pregnancy, and survivorship;
• Psychosocial challenges and advocacy.
Please note: Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Please note the following conflict of interest disclosures:
Ilit Turgeman – Educational activities: AstraZeneca, Bristol-Myers Squibb, Medison, Merck Sharp and Dohme, Merck Serono, Roche. Research grants: Gilead, Pfizer. Conference accommodation: Merck Serono, Roche.
Brian Henick – Honoraria: OncLive/MJH Life Sciences, DAVA Oncology. Consulting or Advisory Role: AstraZeneca, IDEAYA Biosciences, Jazz Pharmaceuticals, Sorrento Therapeutics, Genentech/Roche, Regeneron, Bristol Myers Squibb. Research Funding: NexImmune, Genentech/Roche, Johnson & Johnson/Janssen, Stand Up 2 Cancer, V Foundation.
Laura Mezquita – Educational activities: Bristol-Myers Squibb, AstraZeneca, Roche, Takeda, Janssen, MSD, Radonova. Consulting or Advisory role: Roche, Takeda, Janssen, MSD. Research Grants: Amgen, Inivata, AstraZeneca, Gilead. Travel, Accommodations and Expenses: Bristol-Myers Squibb, Roche, Takeda, AstraZeneca, Janssen.
Keywords:
Global oncology, adolescent and young adult oncology, etiology, genetics, carcinogens, ethnicity, fertility, disparities, microbiome, biomarkers, oncogene driven lung cancer, immunotherapy, toxicity, palliation
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.